2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Castration Resistant Metastatic Prostate Cancer
2
Uterine Cervical Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castration-Resistant Prostate Carcinoma
1
Carcinoma, Squamous Cell
1
Cachexia
1
Interventions
enzalutamide
5
abiraterone
2
Radiotherapy
2
Metastasectomy
2
Abiraterone Acetate
2
testosterone enanthate
1
radium Ra 223 dichloride
1
pembrolizumab
1
disitamab vedotin
1
dactolisib
1
VT-464
1
Radium-223
1
Radiosurgery
1
Prednisone
1
NVP-BKM120
1
Ketoconazole
1
Injections
1
Hydrocortisone
1
Flutamide
1
Cyclophosphamide
1
Crizotinib
1
Control Groups
1
Carboplatin
1
Calcitriol
1
Blood Specimen Collection
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castration-resistant Prostate Cancer
×
testosterone enanthate
×
Clear all
NCT03522064
2026-04-23
HiTeCH
St Vincent's Hospital, Sydney
Phase 2
Recruiting
30 enrolled